Searched for
GLAXOSMITHKLINE PHARMA
More macro headwinds on the cards? Tackle them with core principles: 6 pharma stocks with upside potential of up to 28%There was a time when the Indian pharma story in the US was almost entirely about inspection risk. The US FDA would inspect a plant, a warn...- Stock picks of the week: 5 stocks with consistent score improvement and upside potential of up to 22%As the market grappled with confusion over the Strait of Hormuz, there was more trouble for the bulls. After a few days of respite, another...
- Long-term Investing: Ecosystem with an edge called India; 12 large- mid- and small-cap stocks with upside potential of up to 34%Tactical investing should not be confused with long-term investing. In a world where geopolitical risk, commodity shocks, and uncertainty a...
- GSK's Calpol a well-known trademark: High CourtThe Delhi High Court has recognized GlaxoSmithKline Pharmaceuticals' pain and fever medicine, Calpol, as a well-known trademark. This desig...
- Bombay HC backs GSK in Paxil trademark row against Shreya Life SciencesThe Indian subsidiary of the UK-based GSK PLC had urged the court to cancel the mark used by the local company in pharmaceutical and medici...
- Cipla gets USFDA nod for generic respiratory issues treatment inhalation aerosolPharma major Cipla has secured final approval from the US health regulator for its generic albuterol sulfate inhalation aerosol. This marks...
- I-Sec upgrades GlaxoSmithKline Pharma to Add, lowers target price to Rs 2,250ICICI Securities has raised its rating on GlaxoSmithKline Pharmaceuticals to Add from Hold with a new target price of Rs 2250. GSK Pharma's...
- GlaxoSmithKline Pharma Q4 Results: Firm posts net loss at Rs 55 croreRevenue from operations rose to Rs 810 crore for the fourth quarter compared to Rs 744 crore in the year-ago period, GlaxoSmithKline Pharma...
- GSK Pharma to transfer cancer drug portfolio to Novartis armGlaxoSmithKline Pharmaceuticals board approved transfer of its cancer drugs portfolio to an arm of Novartis in India in return for acquirin...
- GlaxoSmithKline Pharma Q3 net profit declines 61% to Rs 45 croreGlaxoSmithKline Pharmaceuticals today reported a 61.24 per cent decline in its net profit at Rs 45.30 crore for the October-December period.
- Novartis shares up nearly 2% at closeShares of Novartis India ended nearly 2% higher after fair trade regulator CCI approved a multi-billion dollar deal between GlaxoSmithKline...
- GlaxoSmithKline Pharma Q2 Net down 14.56% to Rs 98.29 croreNet sales of the company increased 2.84 per cent to Rs 654.96 cr for the second quarter as compared to Rs 636.86 cr in the same period a ye...
- GSK Pharma shares slump over 8% ahead of closure of open offerShares of GlaxoSmithKline Pharmaceuticals slumped over 8 per cent as the open offer made by its UK-based parent to acquire additional stake...
- FIPB clears GlaxoSmithKline's Rs 6,400 cr FDI proposalFIPB today cleared Rs 6,400 crore FDI proposal of GlaxoSmithKline to acquire additional 24.33 per cent stake in its India arm.
- GlaxoSmithKline seeks FIPB nod to hike stake in Indian armGlaxoSmithKline has approached the FIPB to hike stake in its domestic arm by buying 24.33 per cent for an estimated Rs 6,400 crore.
- GSK's open offer for buying stake in Indian arm from February 7-21GlaxoSmithKline Plc's Rs 6,389.02 crore open offer to pick up 24.33 per cent stake in its Indian arm GlaxoSmithKline Pharma will start from...
- GSK gets Sebi nod for GlaxoSmithKline Consumer open offerThe offer is scheduled to open from Jan 17, according to the announcement made by HSBC on behalf of GSK and is expected to close on January...
- GlaxoSmithKline FY10 net profit up 10.37 pc to Rs 560.57 crGlaxoSmithKline Pharmaceuticals today said its consolidated net profit rose by 10.37 per cent to Rs 560.57 crore for the year ended Decembe...
- GlaxoSmithKline Pharma to launch more vaccines in IndiaDrug major GlaxoSmithKline Pharmaceuticals on MOnday said it would be launching more vaccines in the Indian market.
- Ranbaxy's pact with GSK gives it scope for drug devtRanbaxy Labs had earlier entered into an agreement with GlaxoSmithKline, under which the domestic pharma major was responsible for selectin...
Load More
